Skip to main content

Advertisement

SpringerLink
Log in

Gastric cancer: An update

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Gastric cancer is an aggressive malignancy, which, if metastatic or unresectable, is incurable. However, with metastatic or unresectable disease, patients receive a palliative benefit from chemotherapy. Although the understanding of the biology of this disease is increasing, the development of biologically targeted therapies for gastric cancer has been limited. Cytotoxic therapy remains the standard approach, and although there is agreement on the active agents and active combination chemotherapy regimens, consensus on the standard or reference regimen is lacking. This article reviews the pathophysiology of this disease, placing it in the context of its epidemiology, and the current advances in the treatment of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37:4–66.

    Article  Google Scholar 

  2. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.

    Article  PubMed  Google Scholar 

  3. Theuer CP, Kurosaki T, Ziogas A, et al.: Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer 2000, 89:1883–1892.

    Article  PubMed  CAS  Google Scholar 

  4. Yao JC, Tseng F, Worah S, et al.: Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution’s experience over 15 years. J Clin Oncol 2005, 23:3094–3103. Very nice recent cohort study describing the epidemiology of gastric cancer with particular attention to the racial disparity of this disease.

    Article  PubMed  Google Scholar 

  5. Lauren T: The two histologic main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965, 64:34.

    Google Scholar 

  6. Munoz NP, Correa C, Cuello C, Duque E: Histologic types of gastric carcinoma in high- and low-risk areas. Int J Cancer 1968, 3:809–818.

    Article  PubMed  CAS  Google Scholar 

  7. Keller G, Vogelsang H, Becker I, et al.: Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999, 155:337–342. One of two articles describing the E-cadherin germline mutation as responsible for the development of diffuse hereditary gastric cancer. This is the first gene identified that is associated with a familial form of gastric cancer. See [8].

    PubMed  CAS  Google Scholar 

  8. Suriano G, Mulholland D, de Wever O, et al.: The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion. Oncogene 2003, 22:5716–5719. Together, these two articles describe the E-cadherin germline mutation as responsible for the development of diffuse hereditary gastric cancer. This is the first gene identified that is associated with a familial form of gastric cancer. See [7].

    Article  PubMed  CAS  Google Scholar 

  9. Noffsinger AE, Stemmermann G, Kim OJ, et al.: Gastric cancer: pathology. In Gastrointestinal Oncology: Principles and Practice. Edited by Kelsen DP, et al. Philadelphia: Lippincott Williams & Wilkins; 2002:355–369.

    Google Scholar 

  10. Ebert MP, Fei G, Kahmann S, et al.: Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 2002, 23:87–91.

    Article  PubMed  CAS  Google Scholar 

  11. Ebert MP, Yu J, Hoffmann J, et al.: Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 2003, 21:1708–1714.

    Article  PubMed  CAS  Google Scholar 

  12. Ebert MP, Malfertheiner P: Review article: Pathogenesis of sporadic and familial gastric cancer: implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002, 16:1059–1066.

    Article  PubMed  Google Scholar 

  13. Offerhaus GJ, Giardiello FM, Krush J, et al.: The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992, 102:1980–1982.

    PubMed  CAS  Google Scholar 

  14. Houghton JM, Stoicov C, Nomura S, et al.: Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568–1571. Very important study showing for the first time that Helicobacterrelated gastric cancer is developed from bone marrow-derived stem cells. This work adds to the cumulative evidence that bone marrow-derived mesenchymal stem cells are the cause of all malignancies.

    Article  PubMed  CAS  Google Scholar 

  15. Shah MA, Schwartz GK: The treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004, 4:574–587. A nice and comprehensive review of the treatment of gastric and esophagus cancers. The review also highlights areas of overlap, areas of differences between esophagus and gastric cancer, and areas where the data are limited.

    Article  CAS  Google Scholar 

  16. Janunger KG, Hafstrom L, Nygren P, et al.: A systemic over view of chemotherapy effects in gastric cancer. Acta Oncol 2001, 40:309–326.

    Article  PubMed  CAS  Google Scholar 

  17. Vanhoefer U, Rougier P, Wilke H, et al.: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000, 18:2648–2657.

    PubMed  CAS  Google Scholar 

  18. Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003, 21:54–59.

    Article  PubMed  CAS  Google Scholar 

  19. Icli F, Celik I, Aykan F, et al.: A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer 1998, 83:2475–2480.

    Article  PubMed  CAS  Google Scholar 

  20. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261–267.

    PubMed  CAS  Google Scholar 

  21. Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin, and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999, 80:269–272.

    Article  PubMed  CAS  Google Scholar 

  22. Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002, 20:1996–2004.

    Article  PubMed  CAS  Google Scholar 

  23. Roth A, Maibach R, Martinelli G, et al.: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastri carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology. Ann Oncol 2000, 11:301–306.

    Article  PubMed  CAS  Google Scholar 

  24. Ridwelski K, Gebauer T, Fahlke J, et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001, 12:47–51.

    Article  PubMed  CAS  Google Scholar 

  25. Moiseyenko VM, Ajani JA, Tjuladin SA, et al.: Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma [abstract]. Proc ASCO 2005, 23:4002. An important report of the activity of the addition of docetaxel to cisplatin and 5-fluorouracil in the first-line treatment of advanced gastric cancer. This may be the pivotal trial on which the FDA may approve the use of docetaxel as part of the initial treatment of this disease.

    Google Scholar 

  26. Ajani JA, Baker J, Pisters P, et al.: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma. Cancer 2002, 94:641–646.

    Article  PubMed  CAS  Google Scholar 

  27. Boku N, Ohtsu A, Shimada Y, et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999, 17:319–323.

    PubMed  CAS  Google Scholar 

  28. Ilson D, Saltz L, Enzinger P, et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999, 17:3270–3275.

    PubMed  CAS  Google Scholar 

  29. Pozzo C, Barone C, Szanto J, et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004, 15:1773–1781.

    Article  PubMed  CAS  Google Scholar 

  30. Saltz L, Spriggs D, Schaaf LJ, et al.: Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 1998, 16:3858–3865.

    PubMed  CAS  Google Scholar 

  31. Dank M, Zaluski J, Barone C, et al.: Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st line advanced gastric cancer patients [abstract]. Proc ASCO 2005, 23:4003. An important recent phase III study demonstrating that irinotecan may have equivalent activity to cisplatin when combined with 5-fluorouracil in the first-line treatment of this disease. This regimen may be an important treatment option for patients who are unable to receive cisplatin-based therapy and should replace ELF (etoposide, leucovorin, and 5-fluorouracil) in this regard.

    Google Scholar 

  32. Bouche O, Raoul JL, Bonnentain F, et al.: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LF5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study — FCCD 9803. J Clin Oncol 2004, 22:4319–4328.

    Article  PubMed  CAS  Google Scholar 

  33. Kim DY, Kim JH, Lee S-H, et al.: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously-treated patients with advanced gastric cancer. Ann Oncol, 2003, 14:383–387.

    Article  PubMed  CAS  Google Scholar 

  34. Louvet C, Andre T, Tigaud JM, et al.: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002, 20:4543–4548.

    Article  PubMed  CAS  Google Scholar 

  35. Mauer AM, Kraut EH, Rudin CM, et al.: Phase II study of oxaliplatin, fluorouracil, and leucovorin in metastatic carcinoma of the esophagus/gastric cardia [abstract]. Proc ASCO 2001, 19:650.

    Google Scholar 

  36. Hong YS, Song SY, Cho JY, et al.: A phase II trial of capecitabine (Xeloda) in chemotherapy naive patients with advanced and/or metastatic gastric cancer [abstract]. Proc ASCO 2002, 21:623.

    Google Scholar 

  37. Jatoi A, Murphy BR, Foster NR, et al.: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006, 17:29–34.

    Article  PubMed  CAS  Google Scholar 

  38. Kang HJ, Chang HM, Kim TW, et al.: Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005, 92:246–251.

    PubMed  CAS  Google Scholar 

  39. Tebbutt NC, Norman A, Cunningham D, et al.: Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancers: interim analysis [abstract]. Proc ASCO 2002, 21:523.

    Google Scholar 

  40. Takahashi I, Kakeji Y, Emi Y, et al.: S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 2003, 6(Suppl 1):28–33.

    Article  PubMed  Google Scholar 

  41. Koizumi F, Kurihara M, Nakano S, et al.: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000, 58:191–197.

    Article  PubMed  CAS  Google Scholar 

  42. Chollet P, Schoffski P, Weigang-Kohler K, et al.: Phase II trial of S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003, 39:1264–1270.

    Article  PubMed  CAS  Google Scholar 

  43. Ajani JA, Faust J, Ikeda K, et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005, 23:6957–6965.

    Article  PubMed  CAS  Google Scholar 

  44. Hurwitz H, Fehrenbacher L, Cartwright T, et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract]. ASCO 2003, 22:3646. This is the seminal publication on which bevacizumab was approved for the treatment of colorectal cancer in combination with standard chemotherapy.

    Google Scholar 

  45. Yoshikawa T, Tsuburaya A, Kobayashi O, et al.: Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000, 153:7–12.

    Article  PubMed  CAS  Google Scholar 

  46. Maehara Y, Kabashima A, Koga T, et al.: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000, 128:408–416.

    Article  PubMed  CAS  Google Scholar 

  47. Shah MA, Ilson D, Ramanathan RK, et al.: A multicenter phase II study of irinotecan(CPT), cisplatin,(CIS), and bevacizumab in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [abstract]. Proc ASCO 2005, 23:4025.

    Google Scholar 

  48. Shah MA, Ilson D, Kelsen D: Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan and bevacizumab based therapy. J Clin Oncol 2005, 23:2574–2576.

    Article  PubMed  Google Scholar 

  49. Garcia I, Vizosa F, Martin A, et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10:234–241.

    Article  PubMed  CAS  Google Scholar 

  50. Kopp R, Rothbauer E, Ruge M, et al.: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003, 162:115–132.

    PubMed  CAS  Google Scholar 

  51. Anderson MR, Jankowski JA: The treatment, management and prevention of oesophageal cancer. Expert Opin Biol Ther 2001, 1:1017–1028.

    Article  PubMed  CAS  Google Scholar 

  52. Aloia TA, Harpole DHJ, Reed CE, et al.: Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001, 72:859–866.

    Article  PubMed  CAS  Google Scholar 

  53. Doi T, Koizumi W, Siena S, et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract 1036]. Proc ASCO 2003, 22:258.

    Google Scholar 

  54. Rojo F, Tabernero E, Van Custem E, et al.: Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefinitib (ZD1839) [abstract 764]. Proc ASCO 22:191–0.

  55. Vanhoefer U, Tewes M, Rojo F, et al.: Phase I study of humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004, 22:175–184.

    Article  PubMed  CAS  Google Scholar 

  56. Tebbutt NC, Norman A, Cunningham D, et al.: A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil with PVI plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002, 13:1568–1575.

    Article  PubMed  CAS  Google Scholar 

  57. Ajani JA, Van Custem E, Moiseyenko FC, et al.: Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma: Interim results of a randomized phase III trial (V 325) [abstract]. Proc ASCO 2003, 21:999.

    Google Scholar 

  58. Ajani J, Baker J, Pisters P, et al.: Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2001, 15(Suppl 5):52–54.

    CAS  Google Scholar 

  59. Ilson D, Forastier AA, Arquette M, et al.: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000, 6:316–323.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center and the Weil School of Medicine of Cornell University, 1275 York Avenue, 10021, New York, NY, USA

    Manish A. Shah MD

Authors
  1. Manish A. Shah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manish A. Shah MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, M.A. Gastric cancer: An update. Curr Oncol Rep 8, 183–191 (2006). https://doi.org/10.1007/s11912-006-0018-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0018-4

Keywords

Search

Navigation